On September 18, 2026, Sandoz announced a licensing, development, manufacturing, and commercialization agreement with mAbxience for a proposed biosimilar to Genentech’s HEMLIBRA® (emicizumab). HEMLIBRA® is approved for the treatment of hemophilia A. According to Sandoz, the collaboration would add its first hemophilia biosimilar to the company’s pipeline. Under the agreement,…
